Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Jan 2020)

Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

  • Melissa Petersen,
  • Fan Zhang,
  • Sharon J. Krinsky‐McHale,
  • Wayne Silverman,
  • Joseph H. Lee,
  • Deborah Pang,
  • James Hall,
  • Nicole Schupf,
  • Sid E. O'Bryant

DOI
https://doi.org/10.1002/dad2.12023
Journal volume & issue
Vol. 12, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease (AD) in the general population would apply to adults with Down syndrome (DS). Methods Plasma samples were obtained from 398 members of a community‐based cohort of adults with DS. A total of n = 186 participants were determined to be non‐demented and without mild cognitive impairment (MCI) at baseline and throughout follow‐up; n = 50 had prevalent MCI; n = 42 had prevalent AD. Results The proteomic profile yielded an area under the curve (AUC) of 0.92, sensitivity (SN) = 0.80, and specificity (SP) = 0.98 detecting prevalent MCI. For detecting prevalent AD, the proteomic profile yielded an AUC of 0.89, SN = 0.81, and SP = 0.97. The overall profile closely resembled our previously published profile of AD in the general population. Discussion These data provide evidence of the applicability of our blood‐based algorithm for detecting MCI/AD among adults with DS.

Keywords